Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (271-280 of 356) with videos related to

Pageof 36
Sort By:
Tuberculosis (Edinburgh, Scotland)|April 5, 2011
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosisMorten Ruhwald, Jose Dominguez, Irene Latorre, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosisFrancesca Gobbo, Maria Zingariello, Paola Verachi, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
The European Respiratory Journal|September 3, 2021
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trialKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
Chest|July 25, 2025
Medical Thoracoscopy with versus without Prior Artificial Pneumothorax for Patients with Minimal or Absent Pleural EffusionKaige Wang, Liang Zhou, Min Zhu, et al.
Respiratory Medicine|November 29, 2012
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosisJoyce S Lee, Eunice J Kim, Kara L Lynch, et al.
The European Respiratory Journal|April 23, 2015
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trialsHarold R Collard, Williamson Z Bradford, Vincent Cottin, et al.
BMJ Open Respiratory Research|September 14, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)Toby M Maher, Shervin Assassi, Arata Azuma, et al.
Chest|May 17, 2014
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosisJade Jaffar, Sofia Unger, Tamera J Corte, et al.
Pageof 36

Showing results (271-280 of 356) with videos related to

Sort By:
Pageof 36
Tuberculosis (Edinburgh, Scotland)|April 5, 2011
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosisMorten Ruhwald, Jose Dominguez, Irene Latorre, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosisFrancesca Gobbo, Maria Zingariello, Paola Verachi, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
The European Respiratory Journal|September 3, 2021
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trialKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
Chest|July 25, 2025
Medical Thoracoscopy with versus without Prior Artificial Pneumothorax for Patients with Minimal or Absent Pleural EffusionKaige Wang, Liang Zhou, Min Zhu, et al.
Respiratory Medicine|November 29, 2012
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosisJoyce S Lee, Eunice J Kim, Kara L Lynch, et al.
The European Respiratory Journal|April 23, 2015
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trialsHarold R Collard, Williamson Z Bradford, Vincent Cottin, et al.
BMJ Open Respiratory Research|September 14, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)Toby M Maher, Shervin Assassi, Arata Azuma, et al.
Chest|May 17, 2014
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosisJade Jaffar, Sofia Unger, Tamera J Corte, et al.
Pageof 36